RecruitingPhase 4NCT06941870

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sanofi
Intervention: Efanesoctocog alfa(drug)
Enrollment: 35 enrolled
Eligibility: 12 years · All sexes
Timeline: 2025 – 2027

Study locations (13)

Orthopedic Institute for Children- Site Number : 8400009, Los Angeles, California, United States
Innovative Hematology, Inc.- Site Number : 8400006, Indianapolis, Indiana, United States
University of Iowa- Site Number : 8400004, Iowa City, Iowa, United States
Ohio State University Hospital East- Site Number : 8400001, Columbus, Ohio, United States
Investigational Site Number : 1240003, Hamilton, Ontario, Canada
Investigational Site Number : 1240004, Hamilton, Ontario, Canada
Investigational Site Number : 3920003, Kawasaki, Kanagawa, Japan
Investigational Site Number : 3920002, Hiroshima, Japan
Investigational Site Number : 3920001, Saitama, Japan
Investigational Site Number : 3920004, Tokyo, Japan
Investigational Site Number : 1580003, Kaohsiung City, Taiwan
Investigational Site Number : 1580001, Taichung, Taiwan
Investigational Site Number : 1580002, Taipei, Taiwan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06941870 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials